INDUSTRY INSIDER: J&J MAKES SECOND RUN AT DRUG-COATED STENT MARKET

When Johnson & Johnson lost the bidding war for Guidant earlier this year, it also forfeited its surest path for the development of a new line of drug-coated stents.

NJ.com (http://www.nj.com/business/ledger/index.ssf?/base/business-0/1142488408167360.xml&coll=1)